CT Scan after 130 days of treatment

Date: 3 May 2013

CT scan day 130

Copyright: n/a

Notes:

 

This 30 yr old man with CML underwent a matched BMT from an unrelated donor. Immunosuppressive drugs plus initial antifungal therapy of fluconazole was given followed 2 weeks later with Lip AmB. Patient had persistent coughs and fevers. 
On day63 Caspofungin was given but changed to Voriconazole 200 bd on day96 as a result of worsening LFTs the dose was reduced to 200/d. On day96 progressive changes were seen on CT. On day100 concern re progressive to invasive Aspergillosis /Other mould infections? increased Voriconazole to 400/d.
Patient showed ongoing symptoms of GVHD and continued on methotrexate and cyclosporin. 
Poor LFTs at day 110 lead to change of therapy to Lip. AmB with the aim of reintroducing Voriconazole. On day 108 a bronchoscopy was performed -but no diagnosis could be reached.
Day116 repeat colonoscopy/gastroscopy showed severe architectural damage, active GVHD Ileal and colon biopsy positive for yeast spp.
Day 139 Bronchoscopy – purulent secretions in lingual and LLL, BAL fungal culture negative, PCR was + Aspergillus spp.Day 155 treatment was switched to caspofungin due to patient concern. During the next 40 days the patient was given caspofungin,voriconazole, then caspofungin followed by itraconazole which was not tolerated. On day 226 the patient died.


Images library

Showing 10 posts of 2574 posts found.
  • Title

    Legend

  • Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.

    Nicotine stained fingers - image 1, Nicotine stained fingers - image 2

  • The chemical structure of the novel arylamidine T-2307

    T2307

  • Laryngeal aspergillosis, probably related to inhaled corticosteroids.

    Image A., Image B., Image C., Image D.

  • VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:

    • A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
    • Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
    • Activity against azole-resistant fungal species.
    • Low propensity for P450 drug-drug interactions.

    VL-2397 (ASP2397)

  • SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor

  • Biafungin acetate, a new echinocandin

    Biafungin acetate, a new echinocandin

  • Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010

    Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010